Jade Biosciences Inc. (JBIO)
NASDAQ: JBIO
· Real-Time Price · USD
10.10
0.10 (1.00%)
At close: May 02, 2025, 9:48 AM
1.00% (1D)
| Bid | 9.61 |
| Market Cap | 531.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 10.36 |
| Volume | 7,421 |
| Avg. Volume (20D) | 18,445 |
| Open | 10.18 |
| Previous Close | 10.00 |
| Day's Range | 9.89 - 10.18 |
| 52-Week Range | 9.02 - 884.98 |
| Beta | 0.00 |
About JBIO
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pip...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2025
Employees 50
Stock Exchange NASDAQ
Ticker Symbol JBIO
Website https://jadebiosciences.com/